Clinical Trials · NCT07734792
Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial
- Phase
- Phase 2/Phase 3
- Recruitment status
- Not Yet Recruiting
- Sponsor
- yifang zhu
- Enrollment
- 430
- Start date
- Aug 2026
- Locations
- 1 site, China
- Primary endpoint
- The primary efficacy outcome: Proportion of patients achieving an excellent functional outcome